MENLO PARK, CA., December 7, 2009 — 5AM Venture Management, LLC of Menlo Park, CA and Waltham, MA is pleased to announce the closing of 5AM Ventures III, L.P., a $200 million venture capital fund focused on early‐stage life science companies. The capital was raised from a broad range of current and new institutional investors including endowments, family offices, foundations, funds‐of‐funds and pension funds.
Formed by successful industry executives and experienced venture capitalists, the 5AM team takes a focused, hands‐on approach to company building. 5AM portfolios are well diversified, including spinouts from established life science companies, innovative platform technologies and companies developing near‐term products. 5AM will continue to focus on early‐stage life science companies with the majority of the investments being made in the discovery and development of novel therapeutics. A meaningful portion of the fund will also be invested in companies developing diagnostics, materials, medical devices and reagents.
5AM’s investment team consists of Managing Partners John Diekman, Ph.D., Scott Rocklage, Ph.D., and Andy Schwab; Venture Partners Mason Freeman, M.D., Richard Ulevitch, Ph.D. and Jim Young, Ph.D.; Principals Mark Colella, Kevin Forrest, Ph.D. and Andrew McMillan, Ph.D. and Associate Jennifer Ma, Ph.D. 5AM’s Finance & Administrative team is led by General Counsel & COO Paul Stone, J.D. and Vice President, Finance, Jenny Lee.
About 5AM Ventures
Founded in 2002, 5AM Ventures is focused on actively investing in next‐generation life science companies. With over $400 million under management, 5AM has invested in 27 early‐stage companies and is currently investing 5AM Ventures III, LP. For more information, please visit www.5amventures.com.
5AM Venture Management LLC
Andy Schwab, Managing Partner, +1‐650‐233‐8604
Copyright © 2017 5AM Venture Management LLC